https://www.selleckchem.com/products/uc2288.html
We primarily present responder patient-level data for functional, cardiac, laboratory and imaging assessments conducted during the follow-up period, with non-responder data presented as supplementary. No further development of miridesap/dezamizumab is planned in amyloidosis. However, long-term follow-up of these patients may provide insight into whether active removal of amyloid deposits has an impact on disease progression. ClinicalTrials.gov, NCT01777243. Registered 28 January 2013, https//clinicaltrials.gov/ct2/show/study/NCT01777243
Like
Comment
Share
